Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. The Company’s main business is engaged in producing and distributing Reconstituted Bone Xenograft (RBX). The RBX is a medical device that accelerates bone healing. The firm distributes its medical devices to hospitals as well as other medical device customers that are not hospitals.
GENX stock price ended at $0 on 星期三, after rising NaN%
On the latest trading day Jan 21, 2026, the stock price of GENX rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by -- shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 10.0K shares were traded, equating to a market value of approximately --.